Repaglinide
- Product NDC
- 62135-948
- 11-digit product format
- 621350948
- Labeler code
- 62135
- Product ID
- 62135-948_342983dc-ded9-2234-e063-6294a90ac97f
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- Repaglinide
- Dosage form
- TABLET
- Route
- ORAL
- Labeler
- Chartwell RX, LLC
- Application
- ANDA078555
- Marketing category
- ANDA
- Marketing start
- 2014-01-22
- Substance
- REPAGLINIDE
- Active strength
- 2 mg/1
- Pharmacologic classes
- Glinide [EPC], Potassium Channel Antagonists [MoA]
- NDC exclude flag
- No
- Listing certified through
- 2026-12-31
- Current FDA listing
- Yes
Additional Listing Data#
- Finished product
- Yes
- Brand name base
- Repaglinide
- Listing expiration
- 2026-12-31
Active Ingredients#
Ingredient, Strength table| Ingredient | Strength |
|---|
| REPAGLINIDE | 2 mg/1 |
Harmonized Identifiers#
Field, Values table| Field | Values |
|---|
| Unii | 668Z8C33LU |
| Rxcui | 200256, 200257, 200258 |
DailyMed Product Concepts#
DailyMed Package Descriptions#
Package NDC, Product, Description table| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|
| 62135-948-90 | Repaglinide | 90 in 1 BOTTLE | TABLET | 90 | | 1 |
DailyMed Dashboard NDC Coverage#
NDC, Dashboard title, SPL version table| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|
| 62135-948 | REPAGLINIDE TABLET [CHARTWELL RX, LLC] | 1 | Current NDC, 1 package rows | 20250504_cb995e92-295e-4638-a064-978211f5afe1.zip |
DailyMed RxNorm Mappings#
Packages#
Package NDC, 11-digit format, Description table| Package NDC | 11-digit format | Description | Units | Marketing start | Sample | Exclude flag | Status |
|---|
| 62135-948-90 | 62135094890 | 90 TABLET in 1 BOTTLE (62135-948-90) | 90 tablet | 2025-04-24 | No | No | Current |